According to FUNDER website data,
92 mutual funds hold Kamhada shares in the amount of NIS 41.49 million
Funds that hold significant holdings in the stock – for the full list of holdings
The following is a change in the holdings of mutual funds in Kamahada shares according to data from FUNDER-MVF
KAMDA Ltd. (NASDAQ and TASE: KMDA), a biopharmaceutical company specializing in plasma-based products, reports today that it has signed an agreement to acquire a plasma collection center and other assets of Blood and Plasma Research Inc. (B&PR), a private company from the town of Beaumont in Texas USA . B&PR’s collection center specializes in collecting antibodies rich in antibodies for the Anti-D product. KamHada manufactures and markets an Anti-D product in international markets. The B&PR collection center is among the few in the US approved by the FDA to supply the raw material required to manufacture this product.
“The acquisition of this center represents our entry into the U.S. plasma collection market and promotes our strategic goal of becoming a unique vertical plasma product company,” Said Amir London, CEO of KamHada. “We plan to significantly expand antibody-rich plasma collection capabilities by investing in a collection center in Beaumont Texas, and by leveraging the existing FDA license for this center to open additional collection centers in the United States.
As evidenced by the increase in sales of our anti-rabies antibody product in the US and other markets, our focus on increasing sales of the anti-D product in international markets, and the rapid pace of development and supply of our experimental antibody preparation as a treatment option for coronary heart disease, we are committed to “We believe that this acquisition represents a significant strategic advancement in our program, and we anticipate that it will enable us to be more competitive in the various markets. We look forward to expanding this growing activity.”
The acquisition, with a total cost of approximately $ 1.63 million, is expected to close during the current quarter, subject to the completion of the closing requirements set forth in the acquisition agreement, and will be made through Kamada Plasma LLC, a new wholly-owned subsidiary of Kamhada, which will conduct U.S. plasma collection operations.
For the full report